Drug-Delivering Aptamers Target Leukemia Stem Cells for One-Two Knockout Punch ... including both accelerated or myeloid blast phases of the ... Tumor-Induced B Cell Changes Reveal Potential ...

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...

Results showed that the antibodies neutralized AML and prolonged survival in four separate mouse models of leukemia. Notably, the antibodies effectively targeted leukemic stem cells in bone ...

A patient with highly aggressive primary acute mast cell leukemia (MCL), a rare subtype of systemic mastocytosis (SM), died 3 months after her diagnosis, according to a case report published recently ...

Acute myeloid leukemia (AML) remains incurable for the majority of patients. AML originates from a rare population of cells, termed leukemic stem cells (LSCs) or leukemia-initiating cells ...

In 2021, research led by Ryan Flynn, MD, PhD, and his mentor, Nobel laureate Carolyn Bertozzi, PhD, opened a new chapter in biology, characterizing a new kind of player on the cell surface: glycoRNAs.

Georgia Cancer Center, Augusta, GA.

Plasma cell leukemia (PCL) is a rare disease that may present de novoor secondary to plasma cell myeloma. Advanced disease and extramedullary involvement are common clinical features at presentation.

As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, ...